Form 4: ClearPoint Neuro CEO Sells Shares Under 10b5-1 Plan

ClearPoint Neuro CEO Joseph Burnett sold 19,951 shares of common stock for a weighted average price of $15.17 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Joseph Burnett, CEO and President of ClearPoint Neuro, Inc., sold 19,951 shares of common stock.
• The sale occurred on February 25, 2026, at a weighted average price of $15.17 per share, with individual sales prices ranging from $15.15 to $15.25.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2025.
• Following the sale, Joseph Burnett directly beneficially owns 193,231 shares and indirectly owns 12,499 shares through the Joseph M. Burnett Trust.
• 934 shares previously held by the Joseph M. Burnett Trust were transferred to Joseph Burnett as direct ownership on February 6, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-scheduled under a 10b5-1 plan, which typically indicates personal financial planning rather than a change in management's confidence in the company.

Future Outlook

No forward-looking statements or guidance were provided in this Form 4 filing.

Management Comments

• Joseph Burnett, CEO and President, executed a pre-arranged sale of 19,951 shares of ClearPoint Neuro common stock.

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under a Rule 10b5-1 plan, are a common practice for executives to manage personal finances and diversify holdings. Such planned transactions typically do not signal a change in management's confidence in the company's future and are routine disclosures for publicly traded companies.

Related Party Transactions

• Joseph M. Burnett indirectly owns 12,499 shares through the Joseph M. Burnett Trust dated 10/20/2022, where he serves as trustee.
• 934 shares previously owned by the Joseph M. Burnett Trust were transferred to Joseph M. Burnett as direct ownership on February 6, 2026.

Stakeholder Impact

• Shareholders will note the insider sale, but the pre-arranged nature under a 10b5-1 plan mitigates potential negative interpretations regarding management's outlook.

Key Dates

Recommendation

The insider sale by CEO Joseph Burnett was conducted under a pre-arranged 10b5-1 plan, which typically signals personal financial management rather than a change in the company's fundamental outlook. This transaction alone does not provide sufficient new information to alter an investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

ClearPoint Neuro, CLPT, insider trading, Form 4, stock sale, Joseph Burnett, CEO, 10b5-1 plan